Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lobaplatin/Etoposide With or Without Anlotinib in ES-SCLC
NCT03700359Phase 2Unknown
- Sponsor
- The First Affiliated Hospital of Guangzhou Medical University
- Start
- Mar 2019
- Primary completion
- Nov 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of anlotinib in Small Cell Lung Cancer (SCLC), sponsored by The First Affiliated Hospital of Guangzhou Medical University. Status: unknown.
02
Drugs
anlotinib
03
Conditions
Small Cell Lung Cancer (SCLC)
Beyond the preview
Go deeper on NCT03700359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03700359.